AGIO News and Press, Agios Pharmaceuticals Inc. From 11/20/25

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 12.0% to $0.085 on volume of 480,945,530 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.1% to $4.13 on volume of 355,767,751 shares Freight Technologies Inc. (FRGT) r...

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 14.5% to $0.0869 on volume of 455,993,718 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.7% to $4.145 on volume of 295,215,577 shares Freight Technologies Inc. (FRGT)...

2025-11-19 14:43:12 ET Investment Overview The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at $23 per share, which translates to a market cap valuation of ~$1.4bn.... Read the full article ...

2025-11-19 14:33:28 ET Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Agios Pharmaceuticals, Inc. (AG...

2025-11-19 13:33:03 ET Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle cell disease drug, mitapavit. The trial was design...

2025-11-19 07:59:53 ET More on Agios Pharmaceuticals Agios Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation Q3 2025 Highlights - Agios Posts Strong Pyrukynd Revenue And Eyes FDA Milestones Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call T...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain cr...

2025-11-04 01:47:36 ET Thesis Agios Pharmaceuticals ( AGIO ) reported 3Q25 earnings last Friday, and overall, it was good viewing. They managed to post a GAAP EPS of -$1.78, beating estimates by $0.12, and a revenue figure of $12.88 million, up 43.8% year-over-year and e...

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate kinase (PK) activat...

2025-10-30 14:07:15 ET More on Agios Pharmaceuticals Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be...